1. Home
  2. ENTX vs OPXS Comparison

ENTX vs OPXS Comparison

Compare ENTX & OPXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • OPXS
  • Stock Information
  • Founded
  • ENTX 2010
  • OPXS 1987
  • Country
  • ENTX Israel
  • OPXS United States
  • Employees
  • ENTX N/A
  • OPXS N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • OPXS Electronic Components
  • Sector
  • ENTX Health Care
  • OPXS Technology
  • Exchange
  • ENTX Nasdaq
  • OPXS Nasdaq
  • Market Cap
  • ENTX 142.0M
  • OPXS 119.1M
  • IPO Year
  • ENTX 2018
  • OPXS N/A
  • Fundamental
  • Price
  • ENTX $3.14
  • OPXS $15.03
  • Analyst Decision
  • ENTX Strong Buy
  • OPXS
  • Analyst Count
  • ENTX 1
  • OPXS 0
  • Target Price
  • ENTX $10.00
  • OPXS N/A
  • AVG Volume (30 Days)
  • ENTX 283.9K
  • OPXS 61.6K
  • Earning Date
  • ENTX 11-07-2025
  • OPXS 12-18-2025
  • Dividend Yield
  • ENTX N/A
  • OPXS N/A
  • EPS Growth
  • ENTX N/A
  • OPXS 23.32
  • EPS
  • ENTX N/A
  • OPXS 0.75
  • Revenue
  • ENTX $166,000.00
  • OPXS $39,481,000.00
  • Revenue This Year
  • ENTX N/A
  • OPXS N/A
  • Revenue Next Year
  • ENTX N/A
  • OPXS N/A
  • P/E Ratio
  • ENTX N/A
  • OPXS $21.46
  • Revenue Growth
  • ENTX 191.23
  • OPXS 21.00
  • 52 Week Low
  • ENTX $1.50
  • OPXS $5.36
  • 52 Week High
  • ENTX $3.22
  • OPXS $17.76
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 71.14
  • OPXS 46.02
  • Support Level
  • ENTX $2.45
  • OPXS $16.22
  • Resistance Level
  • ENTX $3.22
  • OPXS $17.27
  • Average True Range (ATR)
  • ENTX 0.23
  • OPXS 1.18
  • MACD
  • ENTX 0.05
  • OPXS -0.26
  • Stochastic Oscillator
  • ENTX 89.09
  • OPXS 36.85

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About OPXS Optex Systems Holdings Inc.

Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, and light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson and Applied Optics Center Dallas and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor and others.

Share on Social Networks: